These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 8632427)

  • 1. Optimal recognition of neutral endopeptidase and angiotensin-converting enzyme active sites by mercaptoacyldipeptides as a means to design potent dual inhibitors.
    Coric P; Turcaud S; Meudal H; Roques BP; Fournie-Zaluski MC
    J Med Chem; 1996 Mar; 39(6):1210-9. PubMed ID: 8632427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action.
    Fournie-Zaluski MC; Coric P; Thery V; Gonzalez W; Meudal H; Turcaud S; Michel JB; Roques BP
    J Med Chem; 1996 Jun; 39(13):2594-608. PubMed ID: 8691458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mercaptoacyl dipeptides as orally active dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
    Fink CA; Carlson JE; McTaggart PA; Qiao Y; Webb R; Chatelain R; Jeng AY; Trapani AJ
    J Med Chem; 1996 Aug; 39(16):3158-68. PubMed ID: 8759637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Dual inhibition of converting enzyme and neutral endopeptidase: a research new way in the field of hypertension].
    Fournie-Zaluski MC
    C R Seances Soc Biol Fil; 1992; 186(6):612-25. PubMed ID: 1339591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hypertension.
    Fournié-Zaluski MC; Coric P; Turcaud S; Rousselet N; Gonzalez W; Barbe B; Pham I; Jullian N; Michel JB; Roques BP
    J Med Chem; 1994 Apr; 37(8):1070-83. PubMed ID: 8164250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploration of neutral endopeptidase active site by a series of new thiol-containing inhibitors.
    Gomez-Monterrey I; Turcaud S; Lucas E; Bruetschy L; Roques BP; Fournié-Zaluski MC
    J Med Chem; 1993 Jan; 36(1):87-94. PubMed ID: 8421293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Marked difference between angiotensin-converting enzyme and neutral endopeptidase inhibition in vivo by a dual inhibitor of both enzymes.
    Anastasopoulos F; Leung R; Kladis A; James GM; Briscoe TA; Gorski TP; Campbell DJ
    J Pharmacol Exp Ther; 1998 Mar; 284(3):799-805. PubMed ID: 9495836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell surface metallopeptidases involved in blood pressure regulation: structure, inhibition and clinical perspectives.
    Roques BP
    Pathol Biol (Paris); 1998 Mar; 46(3):191-200. PubMed ID: 9769915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New approach in the research of analgesics and antihypertensive agents].
    Roques BP
    Ann Pharm Fr; 1991; 49(6):317-26. PubMed ID: 1842170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and enzymatic evaluation of novel partially fluorinated thiol dual ACE/NEP inhibitors.
    Olimpieri F; Tambaro S; Fustero S; Lazzari P; Sanchez-Roselló M; Pani L; Volonterio A; Zanda M
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4715-9. PubMed ID: 19596577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure.
    Trippodo NC; Robl JA; Asaad MM; Bird JE; Panchal BC; Schaeffer TR; Fox M; Giancarli MR; Cheung HS
    J Pharmacol Exp Ther; 1995 Nov; 275(2):745-52. PubMed ID: 7473162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A computational approach to the study of the binding mode of dual ACE/NEP inhibitors.
    Dimitropoulos N; Papakyriakou A; Dalkas GA; Sturrock ED; Spyroulias GA
    J Chem Inf Model; 2010 Mar; 50(3):388-96. PubMed ID: 20170101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.
    Campbell DJ; Anastasopoulos F; Duncan AM; James GM; Kladis A; Briscoe TA
    J Pharmacol Exp Ther; 1998 Nov; 287(2):567-77. PubMed ID: 9808682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats.
    Gonzalez Vera W; Fournié-Zaluski MC; Pham I; Laboulandine I; Roques BP; Michel JB
    J Pharmacol Exp Ther; 1995 Jan; 272(1):343-51. PubMed ID: 7815350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antihypertensive and natriuretic effects of CGS 30440, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase 24.11.
    Chatelain RE; Ghai RD; Trapani AJ; Odorico LM; Dardik BN; De Lombaert S; Lappe RW; Fink CA
    J Pharmacol Exp Ther; 1998 Mar; 284(3):974-82. PubMed ID: 9495857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening of selected basidiomycetes for inhibitory activity on neutral endopeptidase (NEP) and angiotensin-converting enzyme (ACE).
    Melzig MF; Pieper S; Siems WE; Heder G; Bóttger A; Liberra K; Lindequist U
    Pharmazie; 1996 Jul; 51(7):501-3. PubMed ID: 8774843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New thiol inhibitors of neutral endopeptidase EC 3.4.24.11: synthesis and enzyme active-site recognition.
    Gomez-Monterrey I; Beaumont A; Nemecek P; Roques BP; Fournie-Zaluski MC
    J Med Chem; 1994 Jun; 37(12):1865-73. PubMed ID: 8021926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual metalloprotease inhibitors. 6. Incorporation of bicyclic and substituted monocyclic azepinones as dipeptide surrogates in angiotensin-converting enzyme/neutral endopeptidase inhibitors.
    Robl JA; Cimarusti MP; Simpkins LM; Brown B; Ryono DE; Bird JE; Asaad MM; Schaeffer TR; Trippodo NC
    J Med Chem; 1996 Jan; 39(2):494-502. PubMed ID: 8558518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels.
    Duncan AM; James GM; Anastasopoulos F; Kladis A; Briscoe TA; Campbell DJ
    J Pharmacol Exp Ther; 1999 Apr; 289(1):295-303. PubMed ID: 10087017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension.
    Pham I; Gonzalez W; el Amrani AI; Fournié-Zaluski MC; Philippe M; Laboulandine I; Roques BP; Michel JB
    J Pharmacol Exp Ther; 1993 Jun; 265(3):1339-47. PubMed ID: 8389863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.